- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01093989
Acute vs. Delayed Iron Therapy: Effect on Iron Status, Anemia and Cognition
The research questions to be answered by this study are:
- Is treatment with iron more effective at improving anemia if given at the time of a malaria episode or 1 month after the episode?
- Which treatment timing is associated with more malaria episodes - 1 month delayed treatment or immediate treatment at the time of malaria?
- Does timing of iron treatment affect later thinking processes and behavior?
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The study population in this study will be children who are enrolled in our ongoing study of cerebral malaria and severe malarial anemia, "Pathogenesis of cognitive/neurologic deficits in central nervous system malaria", underway in Kampala, Uganda. The pathogenesis study seeks to address the question of why children with severe malaria have later problems in thinking. The study we are now proposing will build on this study by assessing whether children with severe malaria have iron deficiency, and if they do, whether treatment with iron at the time of malaria is less effective than treatment one month later. We believe that treatment one month later may be more effective because there is data that shows that the inflammation that occurs with a malaria episode may decrease the body's ability to absorb iron in the gut and to send iron to the places it is needed, like the bone marrow and the brain. We are doing this study to see if our hypothesis about more effective iron treatment if it is delayed is correct and assessing anemia prevalence, iron status, and long-term neurobehavioral development as outcomes.
We have three study groups: children with cerebral malaria, children with severe malarial anemia, and healthy community control children. Children found to be iron deficient will be randomized to receive iron (as ferrous sulphate syrup) either immediately or at their one-month follow-up visit. At 1-, 6, and 12-month follow-up visits changes in iron and inflammation indicators will be assessed. At the 6- and 12-month visits, neurocognitive behavior will also be evaluated and compared between the immediate vs. delayed iron groups. Malaria morbidity will be assessed via home visits during the period of iron supplementation and via clinic monitoring for the duration of the study.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Kampala, Ouganda
- Mulago Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
All children must
- Be between the ages of 18 mo and 5 y
- Reside within 20 km of study hospital
Children with cerebral malaria must have
- Coma (BCS < 3)
- P. falciparum on blood smear
- No clinical evidence or other causes of encephalopathy
Children with severe malarial anemia must have
- Hemoglobin < 5 g/dL
- Clinical symptoms of malaria
- P. falciparum on blood smear
Community control children must
- Live in same neighborhood or extended household as a child with severe malaria
- Be within one year of age as a child with severe malaria
Exclusion Criteria:
Cerebral malaria
- WBC > 10
- Positive gram stain or culture
Severe malarial anemia
- Impaired conscious on physical exam
- Seizure activity prior to or during physical exam
- Any other evidence of CNS disease
- All exclusion criteria of CM except no lumbar puncture required
Community control children
- All exclusion criteria for CM
- Any active illness, recent illness, or recovery from illness
- Chronic illness requiring medical care
- Medical abnormalities on screening history of physical exam
- CC control with a positive malaria smear will be treated but will not be excluded from the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Immediate iron
Iron-deficient children will be randomized to receive iron concurrently with anti-malarial treatment or one month later (delayed iron group).
|
Iron therapy will consist of a three-month course of ferrous sulphate syrup.
For children with Hb ≥ 7 g/dL, each daily dose will be based on 2 mg iron/kg body weight.
|
|
Comparateur actif: Delayed iron
|
Iron therapy will consist of a three-month course of ferrous sulphate syrup.
For children with Hb ≥ 7 g/dL, each daily dose will be based on 2 mg iron/kg body weight.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Hemoglobin change, anemia prevalence, and socioemotional behavior in the immediate iron vs. delayed iron groups
Délai: 6 months
|
6 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Chandy C John, M.D., University of Minnesota
Publications et liens utiles
Publications générales
- Blatt DB, Hanisch B, Co K, Datta D, Bond C, Opoka RO, Cusick SE, Michelow IC, John CC. Impact of Oxidative Stress on Risk of Death and Readmission in African Children With Severe Malaria: A Prospective Observational Study. J Infect Dis. 2022 Sep 4;226(4):714-722. doi: 10.1093/infdis/jiac234.
- Cusick SE, Opoka RO, Ssemata AS, Georgieff MK, John CC. Delayed iron improves iron status without altering malaria risk in severe malarial anemia. Am J Clin Nutr. 2020 May 1;111(5):1059-1067. doi: 10.1093/ajcn/nqaa004.
- Cusick SE, Opoka RO, Ssemata AS, Georgieff MK, John CC. Comparison of iron status 28 d after provision of antimalarial treatment with iron therapy compared with antimalarial treatment alone in Ugandan children with severe malaria. Am J Clin Nutr. 2016 Mar;103(3):919-25. doi: 10.3945/ajcn.115.117820. Epub 2016 Feb 3.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 0909M72852
- 1U01HD064698-01 (Subvention/contrat des NIH des États-Unis)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .